- In February 2025, X4 Pharmaceuticals and Taiba Rare announced an exclusive agreement for the distribution and commercialization of XOLREMDI (mavorixafor), an oral, once-daily treatment for WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), in select Middle Eastern countries, including Saudi Arabia, the United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt, pending regulatory approvals in the region.
- In January 2025, X4 Pharmaceuticals announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has validated its Marketing Authorization Application (MAA) for mavorixafor, a treatment for WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), a rare primary immunodeficiency. The application is now under evaluation.
- In January 2025, X4 Pharmaceuticals and Norgine announced an exclusive licensing and supply agreement, under which Norgine will commercialize mavorixafor in Europe, Australia, and New Zealand following regulatory approvals. Mavorixafor, a selective CXCR4 receptor antagonist, is approved in the U.S. and marketed by X4 Pharmaceuticals under the brand name XOLREMDI for patients with WHIM syndrome.
- In April 2024, X4 Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI (mavorixafor) capsules for patients aged 12 and older with WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis) to help increase the number of circulating mature neutrophils and lymphocytes. XOLREMDI, a selective CXC chemokine receptor 4 (CXCR4) antagonist, is the first treatment specifically approved for WHIM syndrome patients.
